Dongwha Pharm.Co.,Ltd (KRX:000020)
5,090.00
-110.00 (-2.12%)
At close: Aug 21, 2026
Dongwha Pharm.Co.,Ltd Revenue
Dongwha Pharm.Co.,Ltd had revenue of 136.93B KRW in the quarter ending June 30, 2026, with 9.52% growth. This brings the company's revenue in the last twelve months to 513.24B, up 6.59% year-over-year. In the year 2025, Dongwha Pharm.Co.,Ltd had annual revenue of 496.39B with 6.78% growth.
Revenue (ttm)
513.24B
Revenue Growth
+6.59%
P/S Ratio
0.27
Revenue / Employee
621.36M
Employees
826
Market Cap
141.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.39B | 31.52B | 6.78% |
| Dec 31, 2024 | 464.87B | 103.77B | 28.74% |
| Dec 31, 2023 | 361.11B | 20.68B | 6.08% |
| Dec 31, 2022 | 340.43B | 47.41B | 16.18% |
| Dec 31, 2021 | 293.02B | 20.94B | 7.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewon Pharmaceutical | 614.64B |
| HANDOK | 560.89B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Ilyang Pharmaceutical Co.,Ltd | 275.51B |
| Kyongbo Pharmaceutical | 269.64B |
| Daihan Pharmaceutical | 211.44B |
| Samil Pharmaceutical Co.,Ltd | 210.51B |
| Hana Pharm | 139.33B |